Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
HANGZHOU, CN / ACCESS Newswire / September 28, 2026 / On 25 September, during the 5th Global Digital Trade Expo held in China, the 2026 Festival of Medical AI hosted by Diagens Technology Co. HK, Diagens‑B, "Diagens Tech") , themed "the Next Decade of Medical AI", brought together Kevin Kelly, futurist and founding editor-in-chief of Wired magazine, and Dr.
World’s First Class III Approval for a Breakthrough Medical Imaging AI: Diagens AI AutoVision® Passes Highest-Level Regulatory Validation, Strengthening Its Technological MoatHANGZHOU, China, May 27, 2026 (GLOBE NEWSWIRE) -- On May 22, Hangzhou Diagens Biotechnology Co., Ltd. announced that its proprietary AI AutoVision® Chromosome Karyotype Assisted Diagnosis Software has officially obtained a Class III Medical Device Registration Certificate from China’s National Medical Products Administratio
Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition from technical validation to large-scale commercialization, with annual revenue reaching RMB 164 million, a year-on-year increase of 133.7%.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.